FDA Accepts Tapinarof Cream sNDA for Atopic Dermatitis Patients Aged 2 Years and Older

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

Related Keywords

Todd Zavodnick ,Dermavant Sciences ,Drug Administration ,Supplemental New Drug Application ,Prescription Drug User Fee Act ,Chief Executive Officer ,Isnda ,Tapinarof ,2001 ,Atopic Dermatitis ,Sad ,Eczema ,Dermavant ,